A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease

This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.

开始日期2024-04-01

申办/合作机构

维眸生物科技（上海）有限公司

CTR20211530

/ Completed临床2期

一项评价1%和5% VVN001滴眼液在中国干眼受试者中安全性和有效性的随机、双盲、溶媒对照、多中心II期研究

主要目的是评价1% VVN001滴眼液和5% VVN001滴眼液的安全性和耐受性，评价1% VVN001滴眼液和5% VVN001滴眼液治疗中、重度干眼的有效性

开始日期2021-11-17

申办/合作机构

维眸生物科技（上海）有限公司

CTR20211267

/ Completed临床1期

一项评价1%和5% VVN001滴眼液在健康成年受试者中的安全性、耐受性和药代动力学的随机、双盲、溶媒对照、剂量爬坡、单中心的I期临床试验

主要目的是评价单剂及多剂给药的1%和5% VVN001滴眼液在健康成年受试者中的安全性和耐受性；此外，评价1%和5% VVN001滴眼液在健康成年受试者中可检测到的血药浓度；若检测到足够数量的系统暴露量，评价1%和5%滴眼液在健康成年受试者中的药代动力学（PK）。

开始日期2021-08-16

申办/合作机构

维眸生物科技（上海）有限公司

100 项与 VVN-001 相关的临床结果

登录后查看更多信息

100 项与 VVN-001 相关的转化医学

登录后查看更多信息

100 项与 VVN-001 相关的专利（医药）

登录后查看更多信息

项与 VVN-001 相关的文献（医药）

2023-04-01·The Ocular Surface

A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease

Article

作者: Evans, David ; Clay, Emma ; El-Harazi, Sherif ; Holland, Edward ; Alpern, Louis ; Smyth-Medina, Robert ; Lu, Caroline ; Goosey, John ; Shen, Wang ; Novack, Gary D. ; Li, Xiao-Yan ; Segal, Bruce ; Korenfeld, Michael ; Tauber, Joseph ; Majmudar, Parag ; Goldberg, Damien ; Abrams, Marc ; Martel, Joseph

PURPOSEEvaluate the initial ocular safety and tolerability and efficacy of VVN001 Ophthalmic Solution (VVN001), a small-molecule antagonist of lymphocyte function-associated antigen-1 (LFA-1), in subjects with dry eye disease (DED).METHODSThis was a multi-center, double-masked, randomized, dose-response, vehicle-controlled, parallel-group study conducted in 170 subjects with DED. Subjects were randomized to receive VVN001 (1% or 5%) or its vehicle, twice-daily in both eyes for 84 days. The primary outcome measure was inferior region corneal fluorescein staining (iCFS, 0-4 scale) at Day 84. Visual Analogue Scale eye dryness (VAS, 0-100 scale) was a secondary outcome.RESULTSThe primary and first secondary outcomes were not met. At Day 84 treatment effects in favor of VVN001 5% relative to its vehicle for iCFS were 0.29 units (p = 0.054), and for VAS were 3.18 units (p = 0.533). In other secondary outcomes, treatment effects in favor of VVN001 5% relative to its vehicle were seen in total CFS (1.61 units, 0-20 scale, p = 0.004) and Schirmer score (1.77 and 2.32 mm, p = 0.049 and p = 0.17 at Days 14 and 28 respectively). Adverse events of incidence 5% or greater in either active treatment group were instillation site pain (3/57, 5.3%), dysgeusia (3/56, 5.4%) and urinary tract infection (3/57, 5.3%).CONCLUSIONSThere were no major safety issues of note. Appropriately powered studies will be required with a priori selection of the efficacy endpoints to evaluate VVN001's therapeutic potential.

2021-04-01·Inflammation2区 · 医学

The Protective Effects of VVN001 on LPS-Induced Inflammatory Responses in Human RPE Cells and in a Mouse Model of EIU

2区 · 医学

Article

作者: Yang, Mingzhu ; Qiu, Ruiqi ; Lei, Bo ; Wang, Weiping ; Yang, Lin ; Liu, Jingyang

To investigate protective effects of VVN001 on lipopolysaccharide (LPS)-induced inflammatory response in human retinal pigment epithelial (RPE) cells and in a mouse model of endotoxin-induced uveitis (EIU), and to explore the underlying mechanisms. Human primary RPE (hRPE) and ARPE-19 cells were pretreated with or without VVN001 for 1 h followed by 10 μg/mL LPS stimulation for 24 h. mRNA, and protein levels of inflammatory cytokines were analyzed with real-time PCR, western blotting, and ELISA. EIU was induced by intravitreal injection of 125 ng LPS in female BALB/c mice. VVN001 eye drops (1%) were locally administrated every 4 h for 24 h after LPS injection. Clinical scores were assessed with a slit lamp. mRNA and protein levels of inflammatory cytokines were investigated simultaneously. Compared with the LPS group, VVN001 pretreatment significantly reduced mRNA expressions of intercellular adhesion molecule-1 (ICAM-1), IL-6, IL-8, TNF-α, IL-1β, IL-18, caspase-1 in hRPE, and ARPE-19 cells. Protein overproduction of ICAM-1, TNF-α, IL-1β, NLRP3, caspase-1 P20, and p-IκBα/IκBα stimulated by LPS was suppressed by VVN001 pretreatment. In vivo, VVN001 significantly reduced the average clinical score from 5.0 to 1.3 in EIU mice. Furthermore, overproduction of ICAM-1, IL-1β, NLRP3, caspase-1 P20, and p-IκBα/IκBα at mRNA and protein levels were remarkably suppressed by VVN001. VVN001 alleviated the inflammatory response induced by LPS both in vitro and in vivo. The effect of anti-inflammation is associated with inhibiting the overproduction of ICAM-1 and blocking the activation of NLRP3 inflammasome and the NF-κB signaling pathway.

项与 VVN-001 相关的新闻（医药）

2024-12-03

·PRNewswire

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery

VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery Statistically and clinically meaningful reductions in inflammation and ocular pain observed as early as Day 3 Very favorable safety profile with low adverse event rate in active groups WENZHOU, China and SAN DIEGO, Dec. 3, 2024 /PRNewswire/ -- VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company focused on developing treatments for ocular diseases, today announced positive topline results from its U.S. Phase 2 clinical trial of VVN461-CS-201, a potent non-steroidal dual JAK1/TYK2 immunomodulator for the treatment of post-operative inflammation following cataract surgery. The multicenter, randomized, double-masked, vehicle-controlled study enrolled 91 subjects who underwent routine unilateral cataract extraction by phacoemulsification and lens replacement (CELR). Subjects were randomized into three groups (VVN461 1.0%, VVN461 0.5%, and vehicle) and received four doses daily (QID) for 14 days. VVN461 demonstrated statistical and clinical improvements across all primary and secondary endpoints compared to vehicle. Key findings include: Primary Endpoint: At Day 14, 60.0% (18/30) (1.0%) and 53.3% (16/30) (0.5%) of subjects in the VVN461 groups achieved anterior chamber cell (ACC) Grade 0 compared to 19.4% (6/31) in the vehicle group (p=0.0012 and p=0.0057, respectively.) Secondary Endpoints: Clinically significant reductions in anterior chamber flare (ACF) and subject-reported ocular pain, with therapeutic effects observed as early as Day 3. Exploratory Findings: Over the 14 days of the study, only 4 subjects (combined active groups) out of 61 in the VVN461 groups required rescue medication, compared to 15 out of 30 in the vehicle group, indicating faster and more effective post-operative healing and improved baseline ocular comfort. The adverse event rate with both concentrations of VVN461 was low, with only mild severity, and similar to its vehicle, confirming VVN461's safety profile. "VVN461's Phase 2 results highlight its potential as a safer alternative to corticosteroids for post-operative inflammation," said Jason Bacharach, M.D., Founder and Director of Research at North Bay Eye Associates. "The positive efficacy of VVN461, combined with its excellent safety profile, addresses a critical need for anti-inflammatory therapies with fewer corticosteroid-associated risks." Traditional corticosteroid eye drops, while effective, are associated with adverse effects such as increased intraocular pressure, delayed wound healing, and ocular infections, particularly with long-term use. VVN461 offers a promising alternative, leveraging its targeted, non-steroidal mechanism to minimize these risks while maintaining anti-inflammatory efficacy. "VVN461 represents a meaningful step forward in ophthalmic anti-inflammatory therapy," said Dr. Wang Shen, CEO of VivaVision. "The reductions in inflammation and ocular pain observed as early as Day3, combined with a favorable safety profile, underscore the potential impact of this therapy for patients. These results provide a strong foundation to advance our efforts around a Phase 3 clinical trial of VVN461 in the U.S." VivaVision is also conducting Phase 2 studies for VVN461 in non-infectious anterior uveitis (NIAU) in China. About VivaVision Biotech Founded in 2016, VivaVision Biotech is a clinical-stage pharmaceutical company dedicated to advancing best-in-class and first-in-indication therapies with additional investigational drug candidates for ocular diseases. The company's leading pipeline assets include: VVN461: non-steroidal dual JAK1/TYK2 immunomodulator for post-operative inflammation after cataract surgery and non-infectious anterior uveitis. VVN001: an investigational treatment for dry eye syndrome. VVN1901: a therapy targeting neurotrophic keratitis VVN481: a non-steroidal dual JAK1/TYK2 inhibitor for suprachoroidal delivery targeting treatment of posterior/pan-uveitis In addition to its pipeline, VivaVision is actively engaged in the discovery and development of additional therapies for anterior and posterior segment eye diseases to address unmet patient needs. For more information, please visit . US Media Contact Kellie Shuck, RHMM Inc. Phone: +1 682-553-7283 Email: [email protected] China Media Contact Ruby SUN Phone: +86 181-1619-2461 Email: [email protected] SOURCE VIVAVISION BIOTECH LTD WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床2期

2024-08-06

·PRNewswire

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization. Recently, Viva Biotech's portfolio companies have new updates. Keep reading for more details. Nerio Therapeutics, A Viva Biotech's Portfolio Company, Was Successfully Acquired by Boehringer Ingelheim for $1.3 Billion San Diego, California - On July 29, 2024, Boehringer Ingelheim announced the addition of an innovative preclinical program with the acquisition of Nerio Therapeutics Inc. ("Nerio"), which is invested and incubated by Viva BioInnovator (VBI), for a total of up to USD 1.3 billion. Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio to achieve its goal of improving cancer patient outcomes. Dr. Han Dai, Chief Innovation Officer (CIO) of Viva Biotech and Head of Viva BioInnovator, stated, "Nerio has successfully leveraged the founding team's extensive R&D experience in targeting phosphatases to develop innovative and highly selective PTPN2/N1 phosphatase inhibitors for tumor immunotherapy. This achievement addresses the challenges of selectivity and druggability of phosphatase inhibitors. We are delighted to have invested in and supported Nerio's growth from proof of concept to preclinical research. The acquisition by Boehringer Ingelheim is a strong validation of our investment strategy and the comprehensive post-investment support we provide. With Boehringer Ingelheim's deep expertise in phosphatases and tumor immunotherapy, we anticipate accelerated development of Nerio's pipeline, ultimately delivering greater benefits to patients." Apeiron to Expand Investment in Synthetic Lethality Pipeline After New Phase in Collaboration with Exscientia San Francisco, USA, and Shanghai, China - On July 18, 2924, Apeiron Therapeutics (Apeiron), invested and incubated by Viva BioInnovator (VBI), announced that it has reached an agreement with Exscientia plc (NASDAQ: EXAI), granting Exscientia full control over GTAEXS617 ('617) and all related intellectual property. This asset is currently in the ELUCIDATE Phase 1/2 clinical trial stage. Under the terms of the agreement, Apeiron will receive an upfront payment of $30 million in cash and equity, in addition to receiving single digit royalties if Exscientia or a third party commercializes '617, which could be worth over $100 million in the upcoming years. Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors Heidelberg, Germany and Seoul, Korea - On July 17, Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, announced that it has entered into a license agreement with SK Biopharmaceuticals, a global biotech company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life's "FL-091" radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers. This licensing deal worth $571.5 million includes an upfront payment, and development and commercial milestones, separate from royalties. Under the terms of the agreement, SK Biopharmaceuticals will in-license the NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091 - as well as its back-up compounds - aimed at developing and commercializing it as an innovative anti-cancer drug. Arthrosi Announces First Patient Dosed in Pivotal Phase 3 Reduce 2 Trial of Lead Compound AR882, and Announces Multiple Presentations at the European League Against Rheumatism (EULAR) Congress 2024 San Diego - On June 27, 2024, Arthrosi Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and Tophi in patients with gout. They announced that it has dosed the first patient in REDUCE 2, a pivotal Phase 3 clinical trial to evaluate reduction of sUA in gout patients. During the 2024 European Congress of Rheumatology (EULAR) Congress held from June 12 to June 15, groundbreaking clinical trial results for AR882, a global Class 1 new drug jointly developed by Arthrosi and ApicHope (300723.SZ), were prominently presented by Dr. Robert Keenan, Chief Medical Officer of Arthrosi, reported the latest data from this study at the conference (Abstract Number: POS0268). The research showed that in the 6 to 12-month extension study conducted on patients with tophi, AR882 demonstrated good safety and tolerability, significantly reduced serum uric acid (sUA) levels, and exhibited continued dissolution of tophi and crystal volume. AR882 showed more significant efficacy and better safety in treating gout patients, including those with clinically visible and subclinical crystal deposits. VivaVision Biotech Enrolls First Subject in VVN001 Phase III Clinical Trial in China Wenzhou, China - VivaVision Biotech, Inc. (hereinafter referred to as "VivaVision"), an innovative Chinese ophthalmic drug development company incubated and invested by Viva BioInnovator (VBI), has announced that the first subject has been successfully enrolled and dosed in the China Phase III clinical trial of its independently developed innovative drug for dry eye disease treatment - VVN001 eye drops, a new generation LFA-1 antagonist. About Nerio Therapeutics Nerio Therapeutics, Inc. is a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets. Nerio has developed novel, potent, and highly selective PTPN2/N1 inhibitors with excellent drug-like properties. Nerio's first-in-class PTPN2/N1 inhibitors enhance immune function and sensitize tumors to pro-inflammatory signals, promoting robust anti-tumor activity. Nerio was founded by Avalon Ventures and had additional financial support from a syndicate including Bregua Corporation, Correlation Ventures, Alexandria Venture Investments and Viva BioInnovator. Nerio was developed in the Avalon BioVentures accelerator, benefiting from their resident expertise in early-stage drug development and comprehensive company support. About Apeiron Therapeutics Apeiron is redefining medical discovery, using artificial intelligence to streamline the drug development process—from target selection to clinical trials. With strategic locations in the San Francisco Bay Area and Shanghai, and significant partnerships in Europe, Apeiron integrates talent and cutting-edge technologies spanning multiple regions. We believe that by pushing the frontiers of biomedical innovation and engaging talent globally we can create breakthrough medicines for the highest unmet medical needs. About Full-Life Technologies Full-Life Technologies ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development. For more information, visit Full-Life's website at . About Arthrosi Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing AR882, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and Tophi in patients with gout. Gout remains a large and growing market with ~ 13M patients in the U.S. alone, ~2M of which have tophaceous gout. AR882 has demonstrated encouraging efficacy and safety compared to SOC in Phase 2 studies as well as impressive results in achieving complete resolution of tophi in a Phase 2b study. Arthrosi is currently advancing AR882 in a pivotal phase 3 program. About VivaVision Biotech VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. VivaVision's current pipeline includes VVN001 for treating dry eye syndrome, VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis. VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases. For more info, visit . SOURCE Viva Biotech Holdings

临床结果临床2期临床3期引进/卖出免疫疗法

2024-08-06

·维亚生物

VIVA朋友圈丨维亚生物投资孵化公司近期发展动态一览

面对不断变化的局势，技术创新依旧是生物医药企业长远发展永恒的主旋律，为企业源源不断地注入生命力，持续推动研发“从0到1”转化以及商业化成功。近期，维亚生物参与投资孵化的企业又有新的动态：Nerio达成重大收购；湃隆生物、辐联科技达成重要合作；Arthrosi、维眸生物研发进展顺利等。 13亿美元交易，维亚生物投资孵化公司Nerio与勃林格殷格翰达成收购加利福尼亚州，圣迭戈——2024年7月29日，勃林格殷格翰公司宣布以最高13亿美元交易收购由维亚生物参与投资孵化的Nerio Therapeutics（“Nerio”）。此次收购将大大增强勃林格殷格翰公司的肿瘤免疫管线，目标是改善癌症患者的治疗效果。维亚生物首席创新官兼维亚生物创新中心负责人戴晗博士：“Nerio依托创始团队在磷酸酶药物多年的深耕和积累，成功开发了创新性高选择性磷酸酶PTPN2/N1抑制剂，用于肿瘤免疫治疗，解决了磷酸酶抑制剂选择性和成药性的痛点。我们很高兴投资、见证并陪伴了Nerio从概念验证到临床前研究这一路的成长。本次与勃林格殷格翰达成收购，也再次验证了维亚投资团队的战略眼光及专业的投后支持。借助勃林格殷格翰在磷酸酶和肿瘤免疫治疗领域的积累，我们相信Nerio管线的研发有望进一步加速，更好地造福病患。” 聚焦“合成致死”，湃隆生物出售CDK7抑制剂权益 2024年7月18日，美国旧金山和中国上海——由维亚生物参与投资孵化的上海湃隆生物科技有限公司（简称：湃隆生物）宣布已与Exscientia plc（NASDAQ：EXAI）达成协议，将其在高选择性口服CDK7抑制剂GTAEXS617（简称: 617）的50%权益出售给Exscientia。该项目正处于ELUCIDATE 1/2期临床试验阶段。根据协议，湃隆生物将获得价值3000万美元的交易对价，其中包括1000万美元的现金，1000万美元的Exscientia股票等，以及高个位数的项目对外许可分成，潜在价值超1亿美元。此外，Exscientia将承担617所有开展中的项目研发费用。辐联科技与SK Biopharmaceuticals就靶向多种实体瘤的创新疗法签署许可协议 2024年7月17日，德国海德堡和韩国首尔——维亚生物被投企业辐联科技有限公司（以下简称“辐联科技”），一家全面整合的国际化放射性药物治疗公司，宣布其与全球生物科技公司SK Biopharmaceuticals签署了一项对外授权许可协议。根据该协议，辐联科技授予SK Biopharmaceuticals对于FL-091放射性药物在全球范围内进行临床研究、开发、生产和商业化的独家权利，针对靶向神经降压素受体1型（NTSR1）阳性的癌症。该项交易总额为5.715亿美元，包含首付款、研发及商业里程碑付款，另有特许权使用费未计算在内。根据协议条款，SK Biopharmaceuticals将授权引进靶向NTSR1的放射性药物偶联物（RDC）项目FL-091及其备选化合物，并将其开发成一款创新型抗肿瘤药物。 Arthrosi宣布在先导化合物AR882的关键性三期REDUCE 2试验中完成首例患者给药，并于此前在2024 EULAR大会上展示AR882溶解痛风石临床试验的成果圣迭戈——由维亚生物参与投资孵化的Arthrosi Therapeutics, Inc.是一家处于研发后期阶段的生物技术公司，正在开发一种潜在的同类最佳、高效且选择性强的新一代URAT1抑制剂，以降低痛风患者的血清尿酸水平，减少痛风发作和痛风石。2024年6月27日，Arthrosi 宣布，其AR882已经在REDUCE 2中给第一位患者用药，REDUCE 2是一项关键的三期临床试验，旨在评估在痛风患者中降低血清尿酸（sUA）的效果。此前6月12日至6月15日，2024欧洲风湿病学大会（EULAR年会）期间，Arthrosi与一品红药业股份有限公司合作在研的全球1类新药AR882临床试验成果重磅亮相。Arthrosi首席医学官Robert Keenan博士在大会上报告了该研究的最新数据（摘要编号：POS0268）。研究表明：AR882在痛风石患者中进行的第6至12个月扩展研究中，患者的安全性和耐受性良好，sUA显著降低，表现出持续的痛风石和晶体体积溶解。AR882治疗痛风患者（包括临床可见及亚临床晶体沉积的患者）疗效更显著、安全性更好。维眸生物招募首位受试者入组VVN001中国III期临床试验中国，温州——由维亚生物参与投资孵化的、中国创新型眼科药物研发公司维眸生物科技（浙江）有限公司（以下简称“维眸生物”）宣布，公司自主研发的干眼症治疗创新药——新一代LFA-1拮抗剂VVN001滴眼液中国III期临床试验已于近日顺利完成首例受试者入组及给药。关于Nerio Therapeutics, Inc. Nerio Therapeutics, Inc.是一家专注于磷酸酶的药物发现及开发公司。磷酸酶是一类著名的难成药，但具有潜在高价值的药物靶点。Nerio已开发出新型、强效且高度选择性的PTPN2/N1抑制剂，具有卓越的药物特性。Nerio的PTPN2/ N1抑制剂为同类首创，可增强免疫功能，使肿瘤对促炎信号更敏感，从而促进强大的抗肿瘤活性。Nerio由 Avalon Ventures 创立，并获得了包括 Bregua Corporation、Correlation Ventures、Alexandria Venture Investments 及维亚生物创新中心在内的投资机构支持。Nerio是依托Avalon BioVentures加速器发展而来，受益于Avalon BioVentures加速器在早期药物开发方面的专长和全面的公司支持。关于湃隆生物湃隆生物以全新方式重新定义药物研发，利用人工智能优化药物研发的全过程—从靶点选择到临床试验。凭借位于上海和旧金山湾区的两大战略研发中心以及与欧洲重要伙伴的合作关系，湃隆生物成功整合跨地区的顶尖人才和尖端技术。我们坚信，通过持续拓展生物医学创新的边界、吸引全球优秀人才，湃隆生物能够为重大未满足的临床需求提供突破性药物解决方案。关于辐联科技辐联科技有限公司（“辐联科技”）是一家全面整合的国际化放射性药物治疗公司，在比利时、德国和中国均设有办事处。辐联科技以全球患者为中心，致力于构建集放射性药物研发、生产和商业化为一体的全产业链核药公司，并通过领先的创新型研究解决现今放射性药物面临的根本性挑战，推动未来疗法发展。辐联科技团队由一支运作高效的企业家团队和经验丰富的科学家组成，他们在生命科学、放射性同位素研究和临床开发方面拥有丰富的成功经验。关于Arthrosi Arthrosi Therapeutics, Inc.总部位于加利福尼亚州圣迭戈，专注于开发AR882，这是一种潜在的同类最佳、强效和选择性的新一代URAT1抑制剂，可降低痛风患者的血清尿酸水平，减少痛风发作和痛风石。痛风仍然是一个巨大且不断增长的市场，仅在美国就有约1300万痛风患者，其中约200万患有痛风石。在2期研究中，AR882与 SOC相比显示出令人鼓舞的疗效和安全性；在2b期研究中，AR882在完全消除痛风石方面也取得了令人瞩目的成果。目前，Arthrosi 正在推进AR882的3期临床试验。关于维眸生物维眸生物是专注于眼科治疗领域的临床阶段创新药公司。公司由国际一流的眼科药物研发专家团队组建，已经建立起独特的眼科创新药研发平台，自主研发的多个创新药产品已经或即将进入临床阶段。更多信息请访问：www.vivavisionbio.com 相关推荐免责声明与孵化企业相关的信息由孵化企业提供, 未经本公司独立验证任何情况下, 本公司不对由于本新闻稿资料不准确或疏漏或使用本新闻稿资料引致的损失和损害承担任何直接和间接的责任(不论是民事侵权行为、合约责任或其他)。维亚生物（01873. HK）成立于 2008 年，向全球创新药研发企业提供从早期基于结构的药物研发到商业化药物生产的一站式综合服务。凭借在基于结构的药物研发（SBDD）技术领域的领先优势，我们向全球合作伙伴提供新药研究阶段的CRO服务，搭建了X射线蛋白晶体技术、冷冻电镜技术（Cryo-EM）、DNA编码化合物库技术（DEL）、亲和力质谱筛选技术（ASMS）、表面等离子共振技术（SPR）、氢氘交换质谱技术（HDX-MS）、AIDD/CADD等多个先进技术平台，并有资深药物化学家与药物发现生物专家领军的团队提供药物设计、药物化学（H2L，LO）、化合物合成、化学分析及纯化、公斤级放大及多肽合成及相应的生物活性测试服务。通过子公司朗华制药，我们提供从临床前开发到商业化生产的一站式CMC/CDMO解决方案。同时，我们专注于发现、投资高潜力生物医药初创公司，以独创的技术服务换取股权（EFS）的商业模式，解决未满足的临床需求。

并购放射疗法引进/卖出免疫疗法

100 项与 VVN-001 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼症	临床3期	中国	维眸生物科技（上海）有限公司	2024-04-01
干眼综合征	临床前	美国	维眸生物科技（上海）有限公司	2020-12-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Ocul Surf	N/A	干眼综合征	-	VVN001 5%	衊築選廠鑰築鬱夢顧構(簾糧繭齋襯淵醖鏇製鑰) = 3/56, 5.4% 窪遞壓餘顧衊窪餘齋蓋 (鹽繭窪鬱顧淵簾範壓廠 ) 更多	-	2023-04-01
NCT04556838 (CTgov)	临床2期	干眼综合征	169	VVN001 Ophthalmic Solution 1% (VVN001, 1%)	範醖糧積鹽齋膚選鹽獵(鏇淵積選壓製網築築鏇) = 鑰衊餘網網選鑰網繭壓艱鹹糧糧糧製蓋繭鏇鬱 (壓築網鏇顧齋襯築衊醖, 積遞鹹鹹壓淵糧齋衊餘 ~ 鬱艱蓋衊窪襯鏇選鏇鏇) 更多	-	2023-02-28
NCT04556838 (CTgov)	临床2期	干眼综合征	169	VVN001 Ophthalmic Solution 5% (VVN001, 5%)	範醖糧積鹽齋膚選鹽獵(鏇淵積選壓製網築築鏇) = 窪遞觸壓築廠選鹽艱選艱鹹糧糧糧製蓋繭鏇鬱 (壓築網鏇顧齋襯築衊醖, 窪範糧遞製鹹簾窪餘膚 ~ 遞顧築艱艱窪願憲襯簾) 更多	-	2023-02-28
AAO2022 人工标引	临床2期	干眼症	170	VVN001 1%	-	积极	2022-09-29
AAO2022 人工标引	临床2期	干眼症	170	VVN001 5%	(觸窪艱艱餘鏇選艱鹹蓋) = 憲襯襯廠鑰壓襯範糧壓遞淵選襯鹽淵網齋鹹憲 (夢醖獵艱淵鹹衊顧範鹹 ) 未达到更多	积极	2022-09-29
ARVO2019	N/A	干眼症	-	VVN001	顧衊顧糧積顧積廠鬱製(齋糧網艱襯繭廠獵齋觸) = 憲獵範憲衊窪獵顧遞構壓選選鑰簾簾鹹膚網鏇 (顧製顧憲壓築鬱淵網選 )	-	2019-07-01